Mad in America

JANUARY 4, 2025

American psychiatry has weathered the crisis; it will not have to confront a public stunned by news of how the oft-cited 67% cumulative remission rate, in the largest and longest study ever done to evaluate depression treatment,” was born of scientific misconduct. Such was the news that TheNew York Times found fit to print.

Pharmaceuticals 145

Pharmaceuticals Neurotransmitters and mental health Sleep and mental health Aging and mental health 145

Mad in America

MARCH 15, 2025

This turn to ketamine is occurring despite the fact that the Food and Drug Administration has repeatedly warned that the FDA has not approved ketamine for the treatment of any psychiatric disorder (though controversially approving esketamine nasal spray).

Neurotransmitters and mental health 103

Neurotransmitters and mental health Trauma and the brain Manufacturing Pharmaceuticals 103

Mad in America

NOVEMBER 6, 2023

667 In an NIMH study of 547 patients that compared six-year outcomes for depressed people treated for the disorder and those who eschewed medical treatment, the treated patients were three times more likely than untreated ones to suffer a cessation of their principal social role and nearly seven times more likely to become incapacitated.

Bipolar disorder 142

Bipolar disorder Neurotransmitters and mental health Genetics and mental health Pharmaceuticals 142